Public market insider selling at HLS Therapeutics (HLS)

Public market insider selling at HLS Therapeutics (T:HLS)

Gregory David Gubitz, a Director, disposed of 175,000 Common Shares on an indirect ownership basis for registered holder Grosvenor Ventures Inc. at a price of $12.000 on August 25th, 2022. This represents a $2,100,000 divestment of the company's shares and an account share holdings change of -77.8%.

HLS Therapeutics is in the Drug Retailers Sub Industry Group under the Consumer Non-Cyclicals Sector.

HLS Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.